Abbisko Cayman Limited (2256.HK)
HKD 7.83
(-6.23%)
HKD 7.83
(-6.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.93 Billion CNY | 12.54% |
| 2022 | -2.21 Billion CNY | 11.18% |
| 2021 | -2.49 Billion CNY | -306.17% |
| 2020 | -613.46 Million CNY | -121.68% |
| 2019 | -276.73 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -305.99 Million CNY | 10.06% |
| 2024 Q1 | -305.99 Million CNY | 84.19% |
| 2023 FY | -1.93 Billion CNY | 12.54% |
| 2023 Q2 | -2.06 Billion CNY | 0.49% |
| 2023 Q1 | -2.07 Billion CNY | 6.39% |
| 2023 Q4 | -1.93 Billion CNY | 0.55% |
| 2023 Q3 | -1.94 Billion CNY | 5.59% |
| 2022 Q2 | -2.44 Billion CNY | 0.46% |
| 2022 Q1 | -2.45 Billion CNY | 1.77% |
| 2022 FY | -2.21 Billion CNY | 11.18% |
| 2022 Q4 | -2.21 Billion CNY | 0.45% |
| 2022 Q3 | -2.22 Billion CNY | 9.06% |
| 2021 Q2 | 1.38 Billion CNY | 201.22% |
| 2021 FY | -2.49 Billion CNY | -306.17% |
| 2021 Q1 | -1.36 Billion CNY | 0.0% |
| 2021 Q4 | -2.5 Billion CNY | 0.0% |
| 2021 Q3 | -2.5 Billion CNY | -281.17% |
| 2020 FY | -613.46 Million CNY | -121.68% |
| 2020 Q1 | 297.05 Million CNY | 0.0% |
| 2019 FY | -276.73 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -2434.755% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 136.754% |